Does the rs3798220 CT LPA variant point to higher lipoprotein(a) and altered structure?

Lipoprotein(a) [Lp(a)] is a highly atherogenic, apolipoprotein B [apoB]-containing particle. Its circulating levels and structural properties are heavily influenced by variation in the LPA gene, presenting a unique dual threat of accelerated plaque development and impaired clot breakdown.

Genetic and structural drivers

• The rs3798220 variant: This missense mutation (Ile4399Met) in the LPA gene is a powerful driver of elevated Lp(a) levels, particularly in European populations, where carriers exhibit a 2- to 3-fold increase in circulating concentrations.
• Isoform size and secretion: The rs3798220 variant strongly correlates with fewer kringle IV type-2 (KIV-2) repeats, resulting in smaller apo(a) isoform sizes. These smaller proteins are secreted far more efficiently by the liver, driving genetic overproduction. Notably, this structural relationship is ancestry-specific and does not elevate Lp(a) in East or Southeast Asian populations.

Mechanistic pathways of plaque and clot formation

• Plaque progression: Lp(a) serves as the primary carrier of bioactive oxidized phospholipids (OxPLs) in plasma. Upon depositing in the arterial wall, these OxPLs activate TLR/NF-kB pathways and CD36 scavenger receptors, triggering endothelial inflammation, macrophage recruitment, and rapid foam-cell formation.
• Impaired fibrinolysis: The apo(a) component of Lp(a) shares high structural homology with plasminogen but lacks protease activity. It acts as a competitive antagonist, blocking plasminogen binding and tPA-induced fibrinolysis.
• Thrombotic activity: By preventing the conversion of plasminogen to active plasmin, Lp(a) impairs clot dissolution. When combined with Lp(a)-stimulated tissue factor expression on macrophages and platelet activation, this process yields dense, lysis-resistant clots.

Bottom line

• The rs3798220 variant is a robust genetic marker for elevated Lp(a) and smaller apo(a) isoforms in European ancestries, driving a highly reactive phenotype that accelerates arterial plaque progression through OxPL-mediated inflammation while rendering resulting clots highly resistant to natural breakdown.